Welcome to BioSeeker Group!

Strategic Outlook on Protein Kinase Inhibitors in Oncology

Additional Information

Published Date Feb 20, 2006
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 104
PDF Fact Sheet View Fact Sheet for the report Strategic Outlook on Protein Kinase Inhibitors in Oncology in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Strategic Outlook on Protein Kinase Inhibitors in Oncology.

    To find out more about Strategic Outlook on Protein Kinase Inhibitors in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Strategic Outlook on Protein Kinase Inhibitors in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Since the discovery that the v-Src oncogene encoded a protein kinase in 1978, kinases have become a targeted therapy strategy in oncology for the pharmaceutical industry. The perfect date between Gleevec and Chronic Myeloid Leukemia (CML) will be hard to achieve by other inhibitors currently in development, because of CML’s strong link to a sole pathogenic event – the Philadelphia chromosome. Thus, it is expected that multiple inhibitors may have to be used together to effect higher cure rates in cancers with multiple genetic abnormalities.

Scope of this report

  • Drugs according to protein kinase target; Dual or multiple kinase inhibitor analysis
  • Targets according to indication
  • Competitive landscape assessment
  • Protein kinase inhibitors on market
  • Thorough review of the seven largest cancer indications in the field of protein kinase inhibitors


Research and analysis highlights

The number of protein kinase inhibitor (PKI) drugs has risen sharply, as the number of targets. The fiercest competition in PKI drug development is found in breast, lung, leukemia, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.


Key reasons to read this report

  • Understand the clinical and strategic challenges to the commercialization of protein kinase inhibitor treatments
  • Assess opportunities and risks for the continued development of innovative developmental treatments
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug developmentTable of Contents

1 Executive Summary
2 Cancer Highlights
3 Methodology
4 4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables
5 Rationale for Development of Kinase Inhibitors in Oncology
6 Protein Kinase Targets – A Growing Family
6.1 Challenges in Protein Kinase Drug Discovery
6.1.1 Enabling Structure-Based Drug Design is the Key
6.1.2 Specific Kinase Inhibitors without Kinase Profiling?
6.2 Drugs according to Target
6.2.1 Cyclin-dependent Kinase Target Inhibitors
6.2.2 Aurora Kinase Target Inhibitors
6.2.3 Cell Cycle Checkpoint Target Controls Inhibitors
6.2.4 Tyrosine Kinase Receptor Inhibitors
6.2.5 Other Serine/Threonine Kinase Target Inhibitors
6.3 Dual or Multiple Kinase Inhibitor Analysis
6.3.1 Presentation of Drugs Targeting A to F Kinases
6.3.2 Presentation of Drugs Targeting G to T Kinases
6.4 Targets According to Indication
6.4.1 Breast Cancer
6.4.2 Prostate Cancer: What Cannot be Found in the ’Groins’?
6.4.3 Lung Cancer: A Need for Improved Survival Rates
6.4.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but there are Others
6.4.5 Leukemia: Show Me the Power of PKI
6.4.6 Melanoma
6.4.7 Lymphoma: We Are In
7 Growing Competition in the Field
7.1 Big Pharma Outlook: The Race is On
7.1.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
7.1.2 AstraZeneca – Wheeling and Dealing
7.1.3 Pfizer’s Long Look at OSI Pharmaceuticals
7.1.4 GlaxoSmithKline Gains Momentum
7.2 Strategic Deals Creating Competitive Edge
7.2.1 Mergers
7.2.2 Astex – the PKI Switchboard
7.2.3 Big Pharma’s Darling
8 Current Protein Kinase Inhibitors in Therapy
8.1 Mechanism, Target and Developmental History
8.2 Approvals: Indications & Markets
9 Protein Kinase Inhibitors in Drug Development – A Progress Analysis
9.1 Progress Analysis - Breast Cancer
9.2 Progress Analysis - Prostate Cancer
9.3 Progress Analysis - Lung Cancer
9.4 Progress Analysis - Colorectal Cancer
9.5 Progress Analysis - Leukemia
9.6 Progress Analysis – Melanoma
9.7 Progress Analysis - Lymphoma
10 Selected Company profiles
11 Disclaimer
12 Drug Index
13 Company Index

4.1 List of Boxes
Box 1: The Power of Ambit’s Kinase Profiling
Box 2: Summary Terms of the Exelixis Transaction

4.2 List of Figures
Figure 1: Top 10 PKI Drug Developing Companies
Figure 2: Clinical Trial Distribution in Breast Cancer for PKI Drugs
Figure 3: Clinical Trial Distribution in Prostate Cancer for PKI Drugs
Figure 4: Clinical Trial Distribution in Lung Cancer for PKI Drugs
Figure 5: Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
Figure 6: Clinical Trial Distribution in Leukemia for PKI Drugs
Figure 7: Clinical Trial Distribution in Melanoma for PKI Drugs
Figure 8: Clinical Trial Distribution in Lymphoma for PKI Drugs

4.3 List of Tables
Table 1: Overview of Targets in Commercial Development
Table 2: Cyclin-dependent Kinase Targets in Development
Table 3: Aurora Kinase Targets in Development
Table 4: Cell Cycle Checkpoint Targets in Development
Table 5: Epidermal Growth Factor Receptor Targets in Development
Table 6: FMS-like tyrosine kinases and their Synonyms
Table 7: Fms-related Tyrosine Kinase Targets in Development
Table 8: Platelet-derived Growth Factor Receptor Targets in Development
Table 9: Kinase Insert Domain Targets in Development
Table 10: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
Table 11: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
Table 12: Serine/Threonine Kinase Inhibitors in Development
Table 13: Protein Kinase Targets in Clinical Trials for Breast Cancer
Table 14: Protein Kinase Targets in Clinical Trials for Prostate Cancer
Table 15: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 16: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
Table 17: Protein Kinase Targets in Clinical Trials for Leukemia
Table 18: Protein Kinase Targets in Clinical Trials for Melanoma
Table 19: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 20: Drugs in Therapy – Mechanism & Targets
Table 21: Current and Developmental History of PKI Drugs in Therapy
Table 22: Approvals: Indications & Markets
Table 23: Top 10 Drugs in Terms of Number of Clinical Trials
Table 24: List of Cancer Indications Targeted by Protein Kinase Inhibitors
Table 25: PKI Drugs in Development for Breast Cancer
Table 26: PKI Drugs in Development for Prostate Cancer
Table 27: PKI Drugs in Development for Lung Cancer
Table 28: PKI Drugs in Development for Colorectal Cancer
Table 29: PKI Drugs in Development for Leukemia
Table 30: PKI Drugs in Development for Melanoma
Table 31: PKI Drugs in Development for Lymphoma

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Strategic Outlook on Protein Kinase Inhibitors in Oncology.
    To find out more about Strategic Outlook on Protein Kinase Inhibitors in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Strategic Outlook on Protein Kinase Inhibitors in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Melanoma - Targeted Therapeutics
This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. Learn More


Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio of leukemia products. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Renal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Triple Analysis: Lung Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Line of Treatment' category:


Protein Kinase Inhibitors in Oncology Drug Pipeline Update
BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More